Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for China SXT Pharmaceuticals (SXTC) over the last 4 years, with Q1 2025 value amounting to $2.9 million.

  • China SXT Pharmaceuticals' Accumulated Expenses rose 611.32% to $2.9 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.9 million, marking a year-over-year increase of 611.32%. This contributed to the annual value of $2.9 million for FY2025, which is 611.32% up from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Accumulated Expenses of $2.9 million as of Q1 2025, which was up 611.32% from $2.8 million recorded in Q1 2024.
  • In the past 5 years, China SXT Pharmaceuticals' Accumulated Expenses ranged from a high of $3.1 million in Q1 2023 and a low of $2.8 million during Q1 2024
  • For the 3-year period, China SXT Pharmaceuticals' Accumulated Expenses averaged around $2.9 million, with its median value being $2.9 million (2025).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first crashed by 1189.25% in 2024, then soared by 611.32% in 2025.
  • Quarter analysis of 3 years shows China SXT Pharmaceuticals' Accumulated Expenses stood at $3.1 million in 2023, then fell by 11.89% to $2.8 million in 2024, then grew by 6.11% to $2.9 million in 2025.
  • Its last three reported values are $2.9 million in Q1 2025, $2.8 million for Q1 2024, and $3.1 million during Q1 2023.